{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:19:19Z","timestamp":1789132759020,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.neuropharm.2021.108858","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T20:06:51Z","timestamp":1635278811000},"page":"108858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Mice with high FGF21 serum levels had a reduced preference for morphine and an attenuated development of acute antinociceptive tolerance and physical dependence"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9904-442X","authenticated-orcid":false,"given":"Louben","family":"Dorval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-224X","authenticated-orcid":false,"given":"Olufolake A.","family":"Majekodunmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3295-2076","authenticated-orcid":false,"given":"Sophia","family":"Eliseeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4305-5111","authenticated-orcid":false,"given":"Jean M.","family":"Bidlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108858_bib1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1124\/jpet.302.1.374","article-title":"8-Carboxamidocyclazocine: a long-acting, novel benzomorphan","volume":"302","author":"Bidlack","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108858_bib2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0022-3565(25)12847-4","article-title":"Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice","volume":"277","author":"Bilsky","year":"1996","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108858_bib3","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1210\/en.2013-1191","article-title":"Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice","volume":"154","author":"Camporez","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2021.108858_bib4","article-title":"Insights into the mechanisms underlying opioid use disorder and potential treatment strategies","author":"Cao","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2021.108858_bib66","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2007.05.007","article-title":"Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn","volume":"569","author":"Carey","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jpain.2012.06.007","article-title":"Role of P2X7 receptor-mediated IL-18\/IL-18R signaling in morphine tolerance: multiple glial-neuronal dialogues in the rat spinal cord","volume":"13","author":"Chen","year":"2012","journal-title":"J. Pain"},{"key":"10.1016\/j.neuropharm.2021.108858_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pbb.2016.06.006","article-title":"Sex differences in responsiveness to the prescription opioid oxycodone in mice","volume":"148","author":"Collins","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108858_bib7","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2021.108858_bib8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/ALN.0b013e3181c38c25","article-title":"Incidence, reversal, and prevention of opioid-induced respiratory depression","volume":"112","author":"Dahan","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2021.108858_bib9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fnmol.2017.00284","article-title":"Methods used to evaluate pain behaviors in rodents","volume":"10","author":"Deuis","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108858_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cmet.2012.08.002","article-title":"betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism","volume":"16","author":"Ding","year":"2012","journal-title":"Cell Metabol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib11","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/bcp.12676","article-title":"Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study","volume":"80","author":"Dong","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib12","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.neuroscience.2009.10.007","article-title":"Effect of KEPI (Ppp1r14c) deletion on morphine analgesia and tolerance in mice of different genetic backgrounds: when a knockout is near a relevant quantitative trait locus","volume":"165","author":"Drgonova","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2021.108858_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/syn.10238","article-title":"Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat","volume":"50","author":"Fadda","year":"2003","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2021.108858_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004690","article-title":"Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho\/FGFR1c receptor complex","volume":"4","author":"Foltz","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108858_bib70","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1152\/jn.00978.2016","article-title":"The neural control of interlimb coordination during mammalian locomotion","volume":"117","author":"Frigon","year":"2017","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metabol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib16","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib69","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0006-8993(90)90872-9","article-title":"Induction of the c-fos proto-oncogene during opiate withdrawal in the locus coeruleus and other regions of rat brain","volume":"525","author":"Hayward","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2021.108858_bib17","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1111\/bph.14219","article-title":"Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition","volume":"175","author":"Hill","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/FBP.0b013e32835f3d2f","article-title":"Inhibition of Gbetagamma-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward","volume":"24","author":"Hoot","year":"2013","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.brainres.2004.03.056","article-title":"Sex differences in systemic morphine analgesic tolerance following intrathecal morphine injections","volume":"1014","author":"Hopkins","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2021.108858_bib20","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.peptides.2007.10.007","article-title":"The fasting polypeptide FGF21 can enter brain from blood","volume":"28","author":"Hsuchou","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2021.108858_bib21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1124\/jpet.113.204420","article-title":"Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody","volume":"346","author":"Huang","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108858_bib22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metabol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2020.100057","article-title":"AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients","author":"Kaufman","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.neuropharm.2021.108858_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235362","article-title":"A novel selective PPAR\u03b1 modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms","volume":"15","author":"Kawanishi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2021.108858_bib25","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0022-3565(24)38281-3","article-title":"Sex differences in supraspinal morphine analgesia are dependent on genotype","volume":"289","author":"Kest","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108858_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tem.2010.11.003","article-title":"FGF21 reloaded: challenges of a rapidly growing field","volume":"22","author":"Kharitonenkov","year":"2011","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib27","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2021.108858_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-6147(98)01279-6","article-title":"Opioids: first lessons from knockout mice","volume":"20","author":"Kieffer","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2021.108858_bib29","first-page":"4750","article-title":"An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function","volume":"8","author":"Lee","year":"2016","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.neuropharm.2021.108858_bib30","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.metabol.2012.01.012","article-title":"Fibroblast growth factor-21 protects human skeletal muscle myotubes from palmitate-induced insulin resistance by inhibiting stress kinase and NF-kappaB","volume":"61","author":"Lee","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.neuropharm.2021.108858_bib31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nature05453","article-title":"Genome-wide atlas of gene expression in the adult mouse brain","volume":"445","author":"Lein","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2021.108858_bib32","first-page":"61","article-title":"The dopamine system and alcohol dependence","volume":"26","author":"Ma","year":"2014","journal-title":"Shanghai Arch Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108858_bib33","doi-asserted-by":"crossref","first-page":"12183","DOI":"10.1523\/JNEUROSCI.2326-08.2008","article-title":"A novel Gbetagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence","volume":"28","author":"Mathews","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108858_bib34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.npp.1300860","article-title":"Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning","volume":"31","author":"McLaughlin","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108858_bib35","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0014-2999(95)00322-C","article-title":"Inhibition of protein kinase C, but not of protein kinase A, blocks the development of acute antinociceptive tolerance to an intrathecally administered mu-opioid receptor agonist in the mouse","volume":"280","author":"Narita","year":"1995","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108858_bib68","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1523\/JNEUROSCI.12-07-02439.1992","article-title":"Molecular mechanisms of drug addiction","volume":"12","author":"Nestler","year":"1992","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108858_bib36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/syn.890160105","article-title":"Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area","volume":"16","author":"Nisell","year":"1994","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2021.108858_bib37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00213-005-2259-6","article-title":"Susceptibility to conditioned place preference induced by addictive drugs in mice of the C57BL\/6 and DBA\/2 inbred strains","volume":"181","author":"Orsini","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108858_bib38","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/nm.3250","article-title":"FGF21 contributes to neuroendocrine control of female reproduction","volume":"19","author":"Owen","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2021.108858_bib39","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cmet.2014.07.012","article-title":"FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss","volume":"20","author":"Owen","year":"2014","journal-title":"Cell Metabol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tem.2014.10.002","article-title":"Tissue-specific actions of the metabolic hormones FGF15\/19 and FGF21","volume":"26","author":"Owen","year":"2015","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0091-3057(98)00104-X","article-title":"Naloxone-precipitated morphine withdrawal induced place aversions: effect of naloxone at 24 hours postmorphine","volume":"61","author":"Parker","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108858_bib42","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/bja\/aen094","article-title":"Opioids and the control of respiration","volume":"100","author":"Pattinson","year":"2008","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2021.108858_bib43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1101\/gad.184788.111","article-title":"Endocrine fibroblast growth factors 15\/19 and 21: from feast to famine","volume":"26","author":"Potthoff","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.neuropharm.2021.108858_bib44","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.molmet.2016.05.010","article-title":"Fibroblast growth factor 21 has no direct role in regulating fertility in female mice","volume":"5","author":"Singhal","year":"2016","journal-title":"Mol Metab"},{"key":"10.1016\/j.neuropharm.2021.108858_bib45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-009-1672-7","article-title":"Motivational effects of opiates in conditioned place preference and aversion paradigm--a study in three inbred strains of mice","volume":"207","author":"Solecki","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108858_bib46","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1210\/en.2016-1917","article-title":"A novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward \u03b2-klotho, and enhanced efficacy in mice and cynomolgus monkeys","volume":"158","author":"Stanislaus","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2021.108858_bib47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","article-title":"FGF21 regulates sweet and alcohol preference","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metabol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib48","doi-asserted-by":"crossref","DOI":"10.3791\/51785-v","article-title":"Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases","author":"Tatem","year":"2014","journal-title":"JoVE"},{"key":"10.1016\/j.neuropharm.2021.108858_bib49","doi-asserted-by":"crossref","first-page":"601290","DOI":"10.3389\/fendo.2020.601290","article-title":"FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases","volume":"11","author":"Tillman","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib50","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/npp.2009.143","article-title":"Mechanisms of locomotor sensitization to drugs of abuse in a two-injection protocol","volume":"35","author":"Valjent","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108858_bib51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cmet.2015.12.003","article-title":"FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver","volume":"23","author":"von Holstein-Rathlou","year":"2016","journal-title":"Cell Metabol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib52","article-title":"FGF21 attenuated LPS-induced depressive-like behavior via inhibiting the inflammatory pathway","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib53","doi-asserted-by":"crossref","first-page":"PL339","DOI":"10.1016\/0024-3205(94)90022-1","article-title":"Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence","volume":"54","author":"Wang","year":"1994","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108858_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(99)00131-4","article-title":"3-Isobutyl-1-methylxanthine inhibits basal mu-opioid receptor phosphorylation and reverses acute morphine tolerance and dependence in mice","volume":"371","author":"Wang","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib55","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1096\/fj.08-128348","article-title":"Cell-type specific activation of p38 and ERK mediates calcitonin gene-related peptide involvement in tolerance to morphine-induced analgesia","volume":"23","author":"Wang","year":"2009","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2021.108858_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119104","article-title":"Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK\/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice","volume":"10","author":"Weng","year":"2015","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.neuropharm.2021.108858_bib67","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1111\/bph.13873","article-title":"The dynamic interaction between pain and opioid misuse","volume":"175","author":"Wilson-Poe","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib57","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3389\/fpsyt.2018.00545","article-title":"Sugar addiction: from evolution to revolution","volume":"9","author":"Wiss","year":"2018","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108858_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174245","article-title":"Nitric oxide modulates tapentadol antinociceptive tolerance and physical dependence","volume":"907","author":"Woli\u0144ska","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib59","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2021.108858_bib60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0022-3565(24)37187-3","article-title":"The nitric oxide\/cyclic GMP system at the supraspinal site is involved in the development of acute morphine antinociceptive tolerance","volume":"284","author":"Xu","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108858_bib61","first-page":"721","article-title":"Inhibition by naloxone of tolerance and dependence in mice treated acutely and chronically with morphine","volume":"16","author":"Yano","year":"1977","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108858_bib62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.febslet.2008.11.023","article-title":"FGF21 N- and C-termini play different roles in receptor interaction and activation","volume":"583","author":"Yie","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2021.108858_bib63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0741-8329(92)90004-T","article-title":"Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens","volume":"9","author":"Yoshimoto","year":"1992","journal-title":"Alcohol"},{"key":"10.1016\/j.neuropharm.2021.108858_bib64","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0304-3959(01)00353-0","article-title":"Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC gamma mutant mice","volume":"94","author":"Zeitz","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2021.108858_bib65","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00065","article-title":"The starvation hormone, fibroblast growth factor-21, extends lifespan in mice","volume":"1","author":"Zhang","year":"2012","journal-title":"Elife"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821004135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821004135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:15:01Z","timestamp":1758438901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821004135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":70,"alternative-id":["S0028390821004135"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108858","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.30.453845","asserted-by":"object"}]},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mice with high FGF21 serum levels had a reduced preference for morphine and an attenuated development of acute antinociceptive tolerance and physical dependence","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108858"}}